CompletedPhase 1NCT01883076

Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome

Studying Hypoplastic left heart syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Timothy J Nelson, MD, PhD
Principal Investigator: Timothy J Nelson, M.D., Ph.D.
Mayo Clinic
Intervention: autologous cell-based delivery(biological)
Enrollment: 30 target
Eligibility: All sexes
Timeline: 2013 – 2021

Study locations (6)

Children's Hospital Los Angeles, Los Angeles, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Children's Hospital of Minnesota, Minneapolis, Minnesota, United States
Mayo Clinic, Rochester, Minnesota, United States
Oklahoma University Children's Hospital, Oklahoma City, Oklahoma, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Collaborators

University of Oklahoma · Children's Hospital of Philadelphia · Children's Hospitals and Clinics of Minnesota · Children's Hospital Los Angeles · Children's Hospital Colorado · Mayo Clinic

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01883076 on ClinicalTrials.gov

Other trials for Hypoplastic left heart syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hypoplastic left heart syndrome →

← Back to all trials